What We Know About Mu, the WHO’s Latest Variant of Interest
What We Know About Mu, the WHO’s Latest Variant of Interest
The SARS-CoV-2 variant was first detected in January, but its rising prevalence and potential resistance to vaccines has garnered it special attention from the World Health Organization.
What We Know About Mu, the WHO’s Latest Variant of Interest
What We Know About Mu, the WHO’s Latest Variant of Interest

The SARS-CoV-2 variant was first detected in January, but its rising prevalence and potential resistance to vaccines has garnered it special attention from the World Health Organization.

The SARS-CoV-2 variant was first detected in January, but its rising prevalence and potential resistance to vaccines has garnered it special attention from the World Health Organization.

spike protein
Spike Protein Deletions Linked to COVID-19 Surges: Preprint
Spike Protein Deletions Linked to COVID-19 Surges: Preprint
Alejandra Manjarrez | Jun 15, 2021
Researchers find that surges in COVID-19 case numbers are associated with deletions in the SARS-CoV-2 genome in an antigenic site of the spike protein. Some of these mutations are present in vaccine breakthrough infections or reinfections.
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro
Marcus A. Banks | Mar 1, 2021
A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.
First US Case of UK SARS-CoV-2 Variant Detected
First US Case of UK SARS-CoV-2 Variant Detected
Max Kozlov | Dec 30, 2020
Variant B.1.1.7, though likely more contagious than other strains, does not appear to be more deadly.
UPDATED DEC 21
New SARS-CoV-2 Variant Spreading Rapidly in UK
New SARS-CoV-2 Variant Spreading Rapidly in UK
Max Kozlov | Dec 16, 2020
The significance of the variant remains unclear, but experts remain confident that it will not evade the protection offered by a COVID-19 vaccine.
The Promise of mRNA Vaccines
The Promise of mRNA Vaccines
Diana Kwon | Nov 25, 2020
Long before Moderna’s and Pfizer’s COVID-19 shots, scientists had been considering the use of genetically encoded vaccines in the fight against infectious diseases, cancer, and more.
Immunity to SARS-CoV-2 Lasts at Least Six Months, Data Show
Immunity to SARS-CoV-2 Lasts at Least Six Months, Data Show
Ashley Yeager | Nov 23, 2020
Half a year after infection, people who had recovered from COVID-19 had robust antibodies, along with traces of the virus in their gut, which may drive long-lasting immunity.
Scientists Probe Blockers for the Coronavirus Spike Protein
Scientists Probe Blockers for the Coronavirus Spike Protein
Anthony King | Nov 5, 2020
SARS-CoV-2, the virus that causes COVID-19, taps into human proteases such as furin to enter cells. Temporarily inhibiting those enzymes might stymie infection.
Vector-Based Vaccines Come to the Fore in the COVID-19 Pandemic
Vector-Based Vaccines Come to the Fore in the COVID-19 Pandemic
Anthony King | Sep 8, 2020
Adenovirus vectors deliver the genetic instructions for SARS-CoV-2 antigens directly into patients’ cells, provoking a robust immune response. But will pre-existing immunity from common colds take them down?
Modeling Study Flags Species Susceptible to SARS-CoV-2
Modeling Study Flags Species Susceptible to SARS-CoV-2
Anthony King | Aug 26, 2020
Some critically endangered animals are on the list.
Differences in Antibody Responses Linked to COVID-19 Outcomes
Differences in Antibody Responses Linked to COVID-19 Outcomes
Katarina Zimmer | Aug 18, 2020
In a small study of patients hospitalized due to SARS-CoV-2 infection, researchers report distinct early differences between the antibody responses of patients who recovered and those who died, possibly paving the way for a tool to predict disease prognosis.
First Antibody Trial Launched in COVID-19 Patients
First Antibody Trial Launched in COVID-19 Patients
Katarina Zimmer | Jun 2, 2020
In record time, scientists have gone from harvesting antibodies against SARS-CoV-2 from survivors of coronavirus infections to testing the antibodies’ safety as a drug in humans.
COVID-19 Vaccine Researchers Mindful of Immune Enhancement
COVID-19 Vaccine Researchers Mindful of Immune Enhancement
Katarina Zimmer | May 26, 2020
There is no evidence that any of the coronavirus vaccines in development worsen a coronavirus infection rather than confer immunity to it, but the phenomenon is something scientists are closely monitoring.
Moderna’s Coronavirus Vaccine Spurs Immune Response: Early Data
Moderna’s Coronavirus Vaccine Spurs Immune Response: Early Data
Ashley Yeager | May 18, 2020
A clinical trial of the shot in eight volunteers suggests that it is safe and that it generates antibodies that neutralize SARS-CoV-2, but further testing is needed, scientists say.
Crowdsourced Protein Simulation Exceeds Supercomputers’ Power
Crowdsourced Protein Simulation Exceeds Supercomputers’ Power
Shawna Williams | Apr 15, 2020
Folding@Home, currently focused on deciphering the workings of SARS-CoV-2, is the first project to have exascale-level computational muscle.
Scientists Scan for Weaknesses in the SARS-CoV-2 Spike Protein
Scientists Scan for Weaknesses in the SARS-CoV-2 Spike Protein
Chris Baraniuk | Apr 9, 2020
The virus’s tool for prying open host cells is coated in a protective armor of sugar—but gaps may offer vulnerability to disruption by antibodies.
Novel Virus Entry Portal Found
Novel Virus Entry Portal Found
Sabrina Richards | Mar 13, 2013
Researchers identify the target protein of a recently discovered human coronavirus, shedding light on infection and possible interspecies spread.